+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmacovigilance Market Analysis by Type of Methods, by Type of Service, by Drug Development, and by Region - Global Forecast to 2029

  • PDF Icon

    Report

  • 200 Pages
  • September 2022
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5653973
The rising quantity of ADRs and associated consumer hazards, the growing elderly population, and the usage of drugs have increased globally as chronic illnesses including diabetes, cardiovascular, oncological, and respiratory ailments have become more common are some of the primary market drivers. However, internet-based medicine information and the lack of available competent personnel are expected to restrain the market growth.

By Type of Methods

Based on type of methods, the market is segregated into cohort event monitoring, intensified ADR reporting, EHR mining, targeted spontaneous reporting, and spontaneous reporting. In 2021, the targeted spontaneous reporting segment held the highest market share owing to a widely used technique for the quick and low-cost identification of novel, severe, and uncommon ADRs.

By Type of Service

On the basis of type of service, the market is bifurcated into contract outsourcing and in-house. In 2021, the contract outsourcing segment held the highest market share due to the quickly developing CROs offering complete clinical trial services, and the advantages of outsourcing, including resource flexibility, a decrease in upfront costs, a decrease in fixed costs, and risk reduction.

By Drug Development

Based on drug development, the market is divided into preclinical studies, phase i, phase ii, phase iii, and phase iv, or post-marketing surveillance. In 2021, the phase iv or post-marketing surveillance segment held the highest market share owing to unfavorable drug responses abeingmost frequently seen.

Regional Markets

In 2021, North America had the greatest share of the market due to growing spending by key stakeholders on the development of innovative drugs, the growing rate of drug addiction and adverse drug responses is a primary cause of illness and mortality, and the existence of major manufacturers of pharmaceuticals and medical equipment. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to the increasing investments and encouraging government programs to satisfy the needs of the populace, raising patient consciousness, the accessibility of different outsourcing companies, and increased output, reduced costs, and sharing of resources.

Competitor Insights

Some of the key players operating in the pharmacovigilance market are Accenture (Ireland), ArisGlobal (US), Capgemini (France), Cognizant (US), FMD K&L (US), IBM Corporation (US), ICON plc. (Ireland), IQVIA (US), ITClinical (Portugal), Laboratory Corporation of America Holdings (US), Linical Accelovance (US), PAREXEL International Corporation (US), TAKE Solutions Ltd. (India), and Wipro Ltd. (India).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type of methods, type of service, and drug development from 2022-2029.

Segmentation: Pharmacovigilance market Analysis Report 2021-2029

Type of Methods (Revenue, USD Million)

  • Cohort Event Monitoring
  • Intensified ADR Reporting
  • EHR Mining
  • Targeted Spontaneous Reporting
  • Spontaneous Reporting

Type of Service (Revenue, USD Million)

  • Contract Outsourcing
  • In-house

Drug Development (Revenue, USD Million)

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
1.4.1. Research Models
1.4.1.1. Bottom-up Approach
1.4.1.2. Top-down Approach
1.4.1.3. Data Triangulation
1.4.2. Data Procurement
1.4.2.1. Internal Database
1.4.2.2. Secondary Research
1.4.2.3. Purchased Database
1.4.2.4. Primary Research
1.4.3. Data Analysis
1.4.3.1. Data Validation
1.4.3.2. Market Size Estimation
1.4.3.3. Market Forecast Model
1.4.4. Quality Assessment
2. Introduction: Pharmacovigilance
3. Executive Summary
3.1. Global Market Scenario
3.2. Segment Market Scenario
3.3. Geographic Market Scenario
3.4. COVID-19 Impact
3.5. Competitive Landscape
4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.1.5. Driver 5
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.2.4. Restraint 4
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.3.4. Opportunity 4
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.4.4. Trend 4
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3
4.5.4. Challenge 4
5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. Value Chain Analysis
5.4. SWOT Analysis
5.5. Benchmark
6. COVID-19 Impact Analysis: Pharmacovigilance Market
6.1. COVID-19: Overview
6.2. COVID-19 Impact on the Global Market
6.3. COVID-19 Impact on the Regional Markets
7. Market Analysis by Type of Methods
7.1. Cohort Event Monitoring
7.1.1. Cohort Event Monitoring Market Forecast, 2021-2029 (USD Million)
7.2. Intensified ADR Reporting
7.2.1. Intensified ADR Reporting Market Forecast, 2021-2029 (USD Million)
7.3. EHR Mining
7.3.1. EHR Mining Market Forecast, 2021-2029 (USD Million)
7.4. Targeted Spontaneous Reporting
7.4.1. Targeted Spontaneous Reporting Market Forecast, 2021-2029 (USD Million)
7.5. Spontaneous Reporting
7.5.1. Spontaneous Reporting Market Forecast, 2021-2029 (USD Million)
8. Market Analysis by Type of Service
8.1. Contract Outsourcing
8.1.1. Contract Outsourcing Market Forecast, 2021-2029 (USD Million)
8.2. In-house
8.2.1. In-house Market Forecast, 2021-2029 (USD Million)
9. Market Analysis by Drug Development
9.1. Preclinical Studies
9.1.1. Preclinical Studies Market Forecast, 2021-2029 (USD Million)
9.2. Phase I
9.2.1. Phase I Market Forecast, 2021-2029 (USD Million)
9.3. Phase II
9.3.1. Phase II Market Forecast, 2021-2029 (USD Million)
9.4. Phase III
9.4.1. Phase III Market Forecast, 2021-2029 (USD Million)
9.5. Phase IV or Post Marketing Surveillance
9.5.1. Phase IV or Post Marketing Surveillance Market Forecast, 2021-2029 (USD Million)
10. Regional Market Analysis
10.1. Regional Market Trends
10.2. Regional Market: Comparative Analysis
11. North America Pharmacovigilance Market
11.1. North America Pharmacovigilance Market
11.1.1. North America Market Size and Forecast, 2021-2029 (USD Million)
11.1.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
11.1.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
11.1.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
11.2. U. S. Pharmacovigilance Market
11.2.1. U. S. Market Size and Forecast, 2021-2029 (USD Million)
11.2.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
11.2.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
11.2.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
11.3. Canada Pharmacovigilance Market
11.3.1. Canada Market Size and Forecast, 2021-2029 (USD Million)
11.3.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
11.3.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
11.3.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12. Europe Pharmacovigilance Market
12.1. Europe Pharmacovigilance Market
12.1.1. Europe Market Size and Forecast, 2021-2029 (USD Million)
12.1.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.1.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.1.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.2. Germany Pharmacovigilance Market
12.2.1. Germany Market Size and Forecast, 2021-2029 (USD Million)
12.2.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.2.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.2.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.3. UK Pharmacovigilance Market
12.3.1. UK Market Size and Forecast, 2021-2029 (USD Million)
12.3.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.3.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.3.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.4. France Pharmacovigilance Market
12.4.1. France Market Size and Forecast, 2021-2029 (USD Million)
12.4.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.4.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.4.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.5. Spain Pharmacovigilance Market
12.5.1. Spain Market Size and Forecast, 2021-2029 (USD Million)
12.5.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.5.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.5.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.6. Italy Pharmacovigilance Market
12.6.1. Italy Market Size and Forecast, 2021-2029 (USD Million)
12.6.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.6.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.6.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
12.7. Rest of Europe Pharmacovigilance Market
12.7.1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
12.7.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
12.7.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
12.7.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13. Asia Pacific Pharmacovigilance Market
13.1. Asia Pacific Pharmacovigilance Market
13.1.1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
13.1.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.1.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.1.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.2. Japan Pharmacovigilance Market
13.2.1. Japan Market Size and Forecast, 2021-2029 (USD Million)
13.2.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.2.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.2.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.3. China Pharmacovigilance Market
13.3.1. China Market Size and Forecast, 2021-2029 (USD Million)
13.3.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.3.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.3.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.4. India Pharmacovigilance Market
13.4.1. India Market Size and Forecast, 2021-2029 (USD Million)
13.4.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.4.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.4.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.5. South Korea Pharmacovigilance Market
13.5.1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
13.5.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.5.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.5.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.6. Australia Pharmacovigilance Market
13.6.1. Australia Market Size and Forecast, 2021-2029 (USD Million)
13.6.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.6.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.6.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
13.7. Rest of Asia Pacific Pharmacovigilance Market
13.7.1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
13.7.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
13.7.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
13.7.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
14. Latin America Pharmacovigilance Market
14.1. Latin America Pharmacovigilance Market
14.1.1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
14.1.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
14.1.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
14.1.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
14.2. Brazil Pharmacovigilance Market
14.2.1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
14.2.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
14.2.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
14.2.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
14.3. Mexico Pharmacovigilance Market
14.3.1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
14.3.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
14.3.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
14.3.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
14.4. Argentina Pharmacovigilance Market
14.4.1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
14.4.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
14.4.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
14.4.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
14.5. Rest of Latin America Pharmacovigilance Market
14.5.1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
14.5.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
14.5.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
14.5.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
15. MEA Pharmacovigilance Market
15.1. MEA Pharmacovigilance Market
15.1.1. MEA Market Size and Forecast, 2021-2029 (USD Million)
15.1.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
15.1.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
15.1.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
15.2. GCC Pharmacovigilance Market
15.2.1. GCC Market Size and Forecast, 2021-2029 (USD Million)
15.2.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
15.2.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
15.2.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
15.3. South Africa Pharmacovigilance Market
15.3.1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
15.3.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
15.3.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
15.3.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
15.4. Rest of MEA Pharmacovigilance Market
15.4.1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
15.4.1.1. Market Size and Forecast by Type of Methods, 2021-2029 (USD Million)
15.4.1.2. Market Size and Forecast by Type of Service, 2021-2029 (USD Million)
15.4.1.3. Market Size and Forecast by Drug Development, 2021-2029 (USD Million)
16. Competitor Analysis
16.1. Market Share Analysis, 2021 & 2029
16.2. Competitive Mapping
16.3. Key Players Market Place Analysis
16.4. Major Recent Developments
17. Company Profiles
17.1. Accenture (Ireland)
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financials
17.1.4. Product Benchmarking
17.1.5. Recent Developments
17.2. ArisGlobal (US)
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financials
17.2.4. Product Benchmarking
17.2.5. Recent Developments
17.3. Capgemini (France)
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financials
17.3.4. Product Benchmarking
17.3.5. Recent Developments
17.4. Cognizant (US)
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financials
17.4.4. Product Benchmarking
17.4.5. Recent Developments
17.5. FMD K&L (US)
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financials
17.5.4. Product Benchmarking
17.5.5. Recent Developments
17.6. IBM Corporation (US)
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financials
17.6.4. Product Benchmarking
17.6.5. Recent Developments
17.7. ICON plc. (Ireland)
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financials
17.7.4. Product Benchmarking
17.7.5. Recent Developments
17.8. IQVIA (US)
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financials
17.8.4. Product Benchmarking
17.8.5. Recent Developments
17.9. ITClinical (Portugal)
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financials
17.9.4. Product Benchmarking
17.9.5. Recent Developments
17.10. Laboratory Corporation of America Holdings (US)
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financials
17.10.4. Product Benchmarking
17.10.5. Recent Developments
17.11. Linical Accelovance (US)
17.11.1. Company Snapshot
17.11.2. Company Overview
17.11.3. Financials
17.11.4. Product Benchmarking
17.11.5. Recent Developments
17.12. PAREXEL International Corporation (US)
17.12.1. Company Snapshot
17.12.2. Company Overview
17.12.3. Financials
17.12.4. Product Benchmarking
17.12.5. Recent Developments
17.13. TAKE Solutions Ltd. (India)
17.13.1. Company Snapshot
17.13.2. Company Overview
17.13.3. Financials
17.13.4. Product Benchmarking
17.13.5. Recent Developments
17.14. Wipro Ltd. (India)
17.14.1. Company Snapshot
17.14.2. Company Overview
17.14.3. Financials
17.14.4. Product Benchmarking
17.14.5. Recent Developments
17.15. Company 15
17.15.1. Company Snapshot
17.15.2. Company Overview
17.15.3. Financials
17.15.4. Product Benchmarking
17.15.5. Recent Developments
17.16. Others Prominent Players
18. Conclusion19. Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Accenture (Ireland)
  • ArisGlobal (US)
  • Capgemini (France)
  • Cognizant (US)
  • FMD K&L (US)
  • IBM Corporation (US)
  • ICON plc. (Ireland)
  • IQVIA (US)
  • ITClinical (Portugal)
  • Laboratory Corporation of America Holdings (US)
  • Linical Accelovance (US)
  • PAREXEL International Corporation (US)
  • TAKE Solutions Ltd. (India)
  • Wipro Ltd. (India).